These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26028049)

  • 21. PharmGKB summary: very important pharmacogene information for CFTR.
    McDonagh EM; Clancy JP; Altman RB; Klein TE
    Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096
    [No Abstract]   [Full Text] [Related]  

  • 22. A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel.
    Smith E; Giuliano KA; Shumate J; Baillargeon P; McEwan B; Cullen MD; Miller JP; Drew L; Scampavia L; Spicer TP
    Assay Drug Dev Technol; 2017 Dec; 15(8):395-406. PubMed ID: 29172645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
    Kaiser J
    Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
    [No Abstract]   [Full Text] [Related]  

  • 24. CFTR-NHERF2-LPA₂ Complex in the Airway and Gut Epithelia.
    Zhang W; Zhang Z; Zhang Y; Naren AP
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28869532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CFTR structure and cystic fibrosis.
    Cant N; Pollock N; Ford RC
    Int J Biochem Cell Biol; 2014 Jul; 52():15-25. PubMed ID: 24534272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
    Birault V; Solari R; Hanrahan J; Thomas DY
    Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis.
    Reilly R; Mroz MS; Dempsey E; Wynne K; Keely SJ; McKone EF; Hiebel C; Behl C; Coppinger JA
    Sci Rep; 2017 Aug; 7(1):7642. PubMed ID: 28794469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel pharmacological strategies to treat cystic fibrosis.
    Hanrahan JW; Sampson HM; Thomas DY
    Trends Pharmacol Sci; 2013 Feb; 34(2):119-25. PubMed ID: 23380248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.
    Lubamba B; Dhooghe B; Noel S; Leal T
    Clin Biochem; 2012 Oct; 45(15):1132-44. PubMed ID: 22698459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the regulation of CFTR channels.
    Eckford PD; Bear CE
    Biochem J; 2011 Apr; 435(2):e1-4. PubMed ID: 21726198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR.
    Moniz S; Sousa M; Moraes BJ; Mendes AI; Palma M; Barreto C; Fragata JI; Amaral MD; Matos P
    ACS Chem Biol; 2013 Feb; 8(2):432-42. PubMed ID: 23148778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors targeting the SUMOylation pathway: A patent review 2012‑2015 (Review).
    Zhou Y; Ji C; Cao M; Guo M; Huang W; Ni W; Meng L; Yang H; Wei JF
    Int J Mol Med; 2018 Jan; 41(1):3-12. PubMed ID: 29115401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the SUMO pathway for neuroprotection in brain ischaemia.
    Yang W; Sheng H; Wang H
    Stroke Vasc Neurol; 2016 Sep; 1(3):101-107. PubMed ID: 28959470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Function of SUMOylation and Its Critical Roles in Cardiovascular Diseases and Potential Clinical Implications.
    Du C; Chen X; Su Q; Lu W; Wang Q; Yuan H; Zhang Z; Wang X; Wu H; Qi Y
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetics of Cystic Fibrosis: Clinical Implications.
    Egan ME
    Clin Chest Med; 2016 Mar; 37(1):9-16. PubMed ID: 26857764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small molecule SUMOylation activators are novel neuroprotective agents.
    Krajnak K; Dahl R
    Bioorg Med Chem Lett; 2018 Feb; 28(3):405-409. PubMed ID: 29269215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug bests cystic-fibrosis mutation.
    Ledford H
    Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
    [No Abstract]   [Full Text] [Related]  

  • 39. Degradation of CFTR by the ubiquitin-proteasome pathway.
    Ward CL; Omura S; Kopito RR
    Cell; 1995 Oct; 83(1):121-7. PubMed ID: 7553863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.